1. ¹The Royal College of Radiologists, 38 Portland Place, London, W1B 1JQ UK
2. ²Oncology Centre, Box 193, Addenbrooke's Hospital, Cambridge University Hospitals NHS Trust, Hills Road, Cambridge, CB2 0QQ UK
3. ³The Royal College of Physicians, 11 St Andrews Place, Regent's Park, London, NW1 4LE UK
4. ⁴Medical Oncology Department, The Royal Free Hospital, Pond Street, London, NW3 2QG, UK
5. ⁵Department of Clinical Oncology, The Royal Marsden NHS Foundation Trust, Downs Road, Sutton, Surrey, SM2 5PT UK

Correspondence: Dr Michael V Williams, The Royal College of Radiologists, 38 Portland Place, London, W1B 1JQ, UK. E-mail: michael_williams@rcr.ac.uk

Received 18 April 2008; Revised 16 June 2008; Accepted 30 June 2008.

Abstract

This audit was conducted to measure waiting times for systemic cancer therapy across the United Kingdom. All patients, aged 16 years or older, commencing their first course of systemic therapy between 13 November and 19 November 2006 were eligible for inclusion. Data on 936 patients from 81 hospital sources were collected. Systemic therapy is largely given in compliance with national waiting time targets. In terms of the Joint Council for Clinical Oncology (JCCO) targets, 84% of patients commence treatment within 21 days and 98% of patients complied with the Department of Health target that treatment should follow within 31 days of the decision being agreed with the patient. Only 76% complied with the Department of Health 62-day target from GP referral to first definitive treatment. However, the date of urgent referral by the GP was not submitted for most patients in our survey, leaving a sample of only 84 out of 936 patients (9% of total) suitable for this analysis. There was only a 3- to 5-day difference between the waiting times for systemic therapy for patients categorised as urgent compared with routine. Locally agreed definitions had little impact on patients' priority for treatment. This audit has established a baseline measurement of waiting times for systemic therapy across the United Kingdom. The continuing introduction of novel therapies is likely to have a significant effect on the service and we recommend that service managers model the likely impact on resource requirements. In addition, urgent treatment should be clearly defined as that required within 24 h (maximum 48 h) to avoid the risk of clinical deterioration, particularly in patients with acute leukaemia, lymphoma or germ cell tumour.